Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 9/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19065555 | 1.00 | FGFR3 (0.43) | FGFR3KDRIRAK4METLRRK2 | |
| Trifluoroacetic Acid SCHEMBL19065679 | 0.95 | IRAK4 (0.45) | FGFR3KDRIRAK4METLRRK2 | |
| Trifluoroacetic Acid SCHEMBL29675603 | 0.95 | IRAK4 (0.45) | FGFR3KDRIRAK4METLRRK2 | |
| SCHEMBL19065254 | 0.92 | LRRK2 (0.45) | FGFR3KDRIRAK4LRRK2ALK | |
| Trifluoroacetic Acid SCHEMBL29675739 | 0.87 | MET (0.49) | IRAK4METFLT3ALK | |
| Trifluoroacetic Acid SCHEMBL19065673 | 0.87 | MET (0.49) | IRAK4METFLT3ALK | |
| SCHEMBL19065271 | 0.87 | ALK (0.51) | IRAK4METLRRK2ALKMKNK1 | |
| Trifluoroacetic Acid SCHEMBL19065542 | 0.81 | NPY5R (0.44) | METNPY5R | |
| Trifluoroacetic Acid SCHEMBL29675357 | 0.81 | NPY5R (0.44) | METNPY5R | |
| Trifluoroacetic Acid SCHEMBL19065464 | 0.80 | NPY5R (0.39) | METFLT3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | FGFR3 1404/4885KDR 583/4885IRAK4 116/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | FGFR3 1404/4885KDR 583/4885IRAK4 116/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | FGFR3 1404/4885KDR 583/4885IRAK4 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.